ARTICLE | Company News
Avexa in-licenses Shire HIV compound
January 18, 2005 8:00 AM UTC
Shire (LSE:SHP; SHPGY) granted Avexa (ASX:AVX) a license to SPD754 cytidine analog nucleoside reverse transcriptase inhibitor (NRTI) to treat HIV. SPD754 has completed Phase IIa trials. Avexa is respo...